Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
Etravirine is a next generation nonnucleoside reverse transcriptase inhibitor with activity against nonnucleoside reverse transcriptase inhibitor resistant HIV-1 virus. Susceptibility and virological response to etravirine is dependent on the type and number of nonnucleoside reverse transcriptase inhibitor resistance-associated mutations. We examined the predicted susceptibility of etravirine in patients experiencing virological failure secondary to nonnucleoside reverse transcriptase inhibitor resistance in our patient cohort.
Scott
C
C
St. Stephens Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Grover
D
D
Nelson
M
M
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D009154:Mutation; D009570:Nitriles; D011724:Pyridazines / Q000627:therapeutic use*; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D017211:Treatment Failure
D019380:Anti-HIV Agents; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine